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Abstract
Background:  We sought to quantify the impact of patient characteristics on complications and
health care costs associated with influenza and influenza-like illness (ILI) in a nonelderly population.
Methods:  Patients with medical reimbursement claims for influenza in the 1996–1997 season
were identified from the automated database of a large private New England Insurer (NEI).
Influenza care during the 21- day follow-up period was characterized according to age, gender,
vaccine status, co-morbidities, prior influenza/ILI episodes, treatments, and recent health care costs
and related diagnoses.
Results:  There were 6,241 patients. Approximately 20% had preexisting chronic lung disease.
Overall, 23% had health care services for possible complications, among which respiratory
diagnoses were the most common (13%). Two percent of the influenza/ILI episodes involved
hospitalization, with a median stay of five days. Factors most strongly predictive of hospitalizations
and complications were preexisting malignancy (hospitalizations OR = 3.7 and complications OR =
2.4), chronic heart disease (OR = 3.2 and OR = 1.8), diabetes (OR = 2.2 and OR = 1.7) and recent
illnesses that would have counted as complications had they occurred during an influenza/ILI
episode (hospitalizations OR = 3.2 and complications OR = 1.5). The same factors affected
influenza-related costs and total costs of care as dramatically as they affected complication rates.
Conclusions:   Influenza/ILI-related costs are driven by the characteristics that predict
complications of influenza. Patients with chronic illness and those with recent acute respiratory
events are the most likely to experience complications and hospitalizations.
Background
Influenza costs the US some 40,000 deaths, 200,000
hospitalizations, and millions of workdays lost each year.
[1–3] Most deaths (60–90%) due to influenza occur in
patients 65 years and older, but 45–77% of influenza-re-
lated hospitalizations occur in patients younger than 65
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years old [2,4,5]. High complication rates from influenza
in the elderly have also been reported [6,7]. Little is
known about influenza-related morbidity and health
care costs in younger populations and among those with
preexisting conditions such as diabetes, cardiovascular,
or pulmonary disease.
Diagnosis of influenza is typically based on the presence
of symptoms and the temporal association with known
circulating virus. At the time covered by this study, a rap-
id clinic-based diagnostic test was not available. Most re-
search performed in an observational setting utilizes
clinical diagnosis and therefore, includes both influenza
and some influenza-like illnesses (ILI). A clinic-based
study inevitably misses influenza that does not come to
clinical attention. This study therefore provides data on
the burden to the health payor of influenza, ILI, and their
related complications in a population of 2.6 million chil-
dren and adults with various risk profiles. The primary
objective of this study was to examine the role of patient
characteristics that might be predictive of complications
and related health care costs associated with influenza
and ILI.
Methods
Data source
We used the automated claims database of a large private
New England Insurer (NEI). The NEI database contains
medical claims for outpatient and inpatient services and
outpatient pharmacy claims for about 2,600,000 resi-
dents of New England with comprehensive medical and
prescription drug coverage. The number of people over
age 65 is limited, since Medicare beneficiaries do not
participate in NEI.
Each medical claim contains primary and secondary di-
agnoses codes assigned using the International Classifi-
cation of Diseases, ninth Revision (ICD-9) [8]. Up to five
procedure codes are also present on the claim records
and are coded using ICD-9, Current Procedural Termi-
nology (CPT), or Health Care Finance Administration
(HCFA) codes. [8–10] Prescription drugs dispensed are
identified by National Drug Code (NDC), American Hos-
pital Formulary Service (AHFS) therapeutic category,
brand name, and chemical name [11]. The inpatient
transactions contain each service the provider listed on
the claims for reimbursement, such as surgeries, radio-
logic tests, laboratory tests, room and board charges, or
other specific cost items. Inpatient pharmacy costs are
included in the aggregate hospital charges, and cannot
be separated out. Charges by the provider and amounts
paid by the insurer, patient, or other third parties are in-
cluded.
Study population
Patients with a billed diagnosis of influenza (medical
claim with either a primary or secondary ICD-9 diagno-
sis code of 487) meeting the following criteria were des-
ignated as having an influenza/ILI episode for the
ensuing 21 days: 1) diagnosis occurred between the be-
ginning of October 1996 and the end of April 1997; 2) di-
agnosis did not occur on the date of a immunization for
influenza; 3) diagnosis was preceded by at least one year
of continuous health insurance coverage, with no gaps in
coverage that exceeded 30 days; and 4) insurance cover-
age during the 21-day follow up period was continuous.
We will use the term "interval of care" interchangeably
with "episode" to describe this period. Multiple claims
for care of influenza for the same patient occurring with-
in the 21-day follow-up period were taken to be part of a
single episode. We refer to the qualifying influenza diag-
nosis day and the subsequent 21-day follow-up period as
the interval of care throughout this report. The 21-day
period captures the longest likely duration of symptoms
directly caused by the influenza infection (7–10 days)
plus a period to account for the evolution and resolution
of complications of the infection. While a rare, serious
complication could lead to a protracted illness, we felt
that the problem of resolving the relative contributions
of underlying and acute disease in these settings would
introduce substantial error, and provide relatively little
additional information. We will use the term "influenza/
ILI" throughout this manuscript recognizing that medi-
cal claims with an ICD-9 code of 487 include influenza as
well as some cases of ILI.
Characteristics of influenza/ILI-related episodes
We characterized each influenza/ILI episode according
to: (1) age at time of influenza/ILI diagnosis; (2) gender;
(3) recorded influenza immunization status; (4) prior in-
fluenza/ILI episodes during the study period; (5) antivi-
ral influenza treatment (amantadine or rimantadine);
(6) total patient health care costs in the three months be-
fore influenza/ILI diagnosis); (7) co-morbidities for
which health services were received in (a) the 30 days
and (b) the year before influenza/ILI diagnosis (chronic
lung disease, chronic renal disease, diabetes, malignan-
cies, HIV infections, and chronic heart disease); (8) im-
munosuppressive and chronic corticosteroid drug use
during the year before influenza/ILI diagnosis; (9)
health services in the 30 days before influenza/ILI diag-
nosis for conditions that would have been characterized
as complications or manifestations had they occurred
during the influenza/ILI episode (see below). The 30-
day window was chosen on clinical grounds to capture
medical conditions that were unstable, and the one-year
window was intended to capture all active medical con-
ditions. Inevitably, some routine care will have occurred
in the 30-day window, and some conditions treated inBMC Health Services Research 2001, 1:8 http://www.biomedcentral.com/1472-6963/1/8
the past year will not have been active at the time of the
influenza episode.
We evaluated influenza immunizations between Septem-
ber 1, 1996 and the day before the initial influenza/ILI di-
agnosis. Antiviral influenza medications dispensed
within the three days before, the day of, or the three days
after the initial influenza/ILI diagnosis date were noted.
We created this seven-day time window to account for
prescriptions that may have been dispensed for the cur-
rent diagnosis before an office visit (e.g., by telephoned
prescription) or within a few days after an office visit. We
categorized health care costs in the three months before
the influenza/ILI diagnosis in quintile ranges as follows:
(1) $0, (2) up to $87, (3) $87 – $200, (4) $200 – $453
and (5) $453 and above. The mean and median three-
month costs preceding influenza/ILI diagnoses was
$644 and $135, respectively. The underlying co-morbid
conditions we considered included chronic lung disease,
chronic renal disease, diabetes, malignancies, HIV infec-
tions, chronic heart disease, and chronic renal disease.
Complications and manifestations of influenza/ILI
We defined complications and manifestations occurring
on the day of the influenza/ILI diagnosis or during the
21-day follow-up period using individual or combina-
tions of ICD-9 codes to capture respiratory, cardiovascu-
lar, infectious, musculoskeletal, symptoms, and other
diseases. Ambulatory care visits, hospitalizations, proce-
dures, and emergency room visits were included.
Throughout this report, these are referred to as compli-
cations of influenza/ILI. Please see Additional File 1[Ap-
pendix A.doc] for specific ICD9 codes.
Comorbidities
We identified the presence of chronic lung disease,
chronic renal disease, diabetes, malignancies, HIV infec-
tions, and chronic heart disease using algorithms based
on health services utilization, detailed in Additional File
1[Appendix B.doc].
Hospitalizations
Influenza/ILI-related hospitalizations were defined us-
ing the ICD-9 diagnoses codes recorded on the detailed
inpatient claims, categorized as listed above. We calcu-
lated mean and median length of stay in hospital. There
were 10 (out of 115) hospitalizations that continued be-
yond the 21-day follow-up period. For the complications
analysis, these counted in exactly the same manner as
the 105 hospitalizations that were completed within the
21-day follow-up. For the primary cost and duration of
stay analyses data from the 10 extended hospitalizations
were retained only for hospitalized days in the follow-up
period, as an approximate way of partitioning costs for
events with mulitfactorial etiology. Total hospital cost
was multiplied by the proportion of hospital days that fell
within the follow-up period. We also present the total
cost and length of stay without truncation.
Health care costs
We characterized each influenza/ILI interval of care by
total cost and influenza/ILI-related cost. We defined in-
fluenza/ILI-related costs as those associated with ongo-
ing care for influenza/ILI and with complications of
influenza/ILI, including medication costs, which oc-
curred during the influenza/ILI interval of care (see
above list of ICD-9 codes). Influenza/ILI-related medi-
cations were those commonly prescribed for influenza/
ILI symptoms, manifestations and complications (oral,
injectable, ophthalmic and topical antibiotics; antitus-
sives; expectorants, and mucolytic agents; decongest-
ants;aspirin, acetaminophen, ibuprofen, naproxen;
amantadine, rimantadine; beta-agonists; theophylline;
oral, injectable, rectal or inhaled steroids; ipratropium
and cromolyn sodium).
We defined total costs as the sum of total health care
costs for all services incurred during the interval of care.
Costs presented in this report were the sum of the
amount paid by the insurer and the patient. Patient costs
include a patient's deductible, co-payment, coinsurance,
and coordination of benefit amounts. Societal costs and
patient level costs such as lost workdays were not consid-
ered.
Analysis
We used logistic regression modeling to examine the as-
sociation of potential predictive factors with influenza/
ILI-related complications and hospitalizations. These
models permitted adjustment for all of the possible pre-
dictive factors concurrently; no variables were dropped
from the models.
Results
Study population and intervals of care
6,269 persons met eligibility and enrollment criteria;
they experienced 6,660 intervals of influenza/ILI care.
Thirty intervals of care were excluded from the analysis
because they occurred in subgroups with very small
numbers of patients, within which it would have been
impossible to obtain stable disease-specific estimates
(HIV (4 men; 2 women); chronic renal disease (5 men; 7
women) and immunosuppressive therapy (3 men; 10
women)). The remaining 6,630 influenza/ILI intervals
of care (6,241 patients) formed the basis of this analysis.
Ninety-four percent of patients (5,895) had a single epi-
sode. Approximately 5% (308) experienced two episodes
and 1% (30) had three or more during the study period.
In 94% of the intervals of care, influenza/ILI was diag-BMC Health Services Research 2001, 1:8 http://www.biomedcentral.com/1472-6963/1/8
nosed in an outpatient setting. Approximately 5% were
diagnosed in the emergency room and 1% were diag-
nosed upon hospitalization.
Approximately 38% of episodes included outpatient pro-
cedures or services associated with influenza/ILI or
complications. Outpatient dispensings were recorded for
50% of the episodes for the medications commonly pre-
scribed for influenza/ILI symptoms, manifestations, and
complications on the day of or during the 21 days beyond
their diagnosis. Antibiotics were prescribed for 39% of
the episodes. Four percent of the episodes had dispens-
ings of antivirals (amantadine or rimantadine).
Overall, 23% of the influenza/ILI episodes had evidence
of one or more co-morbid conditions occurring in the
year before the influenza/ILI diagnosis. Chronic lung
disease was the most prevalent, observed for approxi-
mately 20% of the influenza/ILI episodes, at every age.
Chronic corticosteroid use, malignancy, chronic heart
disease, and diabetes became more common with ad-
vancing age. In approximately 2% of the influenza/ILI
intervals of care, patients had evidence of multiple co-
morbidities and this rose with higher age groups, reach-
ing 21% for males age 65+ and 17% for females age 65+.
(Table 1).
Table 1: Prevalence of Medication Use and Comorbidities in the Year Before the Influenza Diagnosis
Chronic Chronic Chronic
Age (years) Corticosteroid Malignancy Heart Lung
and Gender Episodes Disease Disease Diabetes Multiple Any
NN % N % N % N % N % N % N %
0–4
Male 648 1 0 0 0 1 0 142 22 0 0 0 0 144 22
Female 573 1 0 0 0 1 0 100 17 0 0 2 0 100 17
5–14
Male 806 0 0 1 0 0 0 185 23 1 0 1 0 186 23
Female 826 1 0 2 0 1 0 173 21 0 0 1 0 176 21
15–24
Male 253 0 0 1 0 0 0 44 17 0 0 0 0 45 18
Female 336 1 0 0 0 0 0 73 22 1 0 0 0 75 22
25–34
Male 284 0 0 1 0 0 0 39 14 1 0 1 0 40 14
Female 445 1 0 0 0 1 0 72 16 5 1 4 1 75 17
35–44
Male 422 3 1 5 1 8 2 59 14 8 2 7 2 74 18
Female 553 3 1 6 1 2 0 98 18 9 2 5 1 113 20
45–54
Male 356 2 1 6 2 19 5 67 19 18 5 16 4 94 26
Female 450 3 1 15 3 9 2 90 20 10 2 12 3 113 25
55–64
Male 209 2 1 6 3 32 15 39 19 18 9 16 8 77 37
Female 299 6 2 14 5 13 4 66 22 24 8 17 6 99 33
65+
Male 57 1 2 7 12 16 28 11 19 8 1
4
12 2
1
29 51
Female 113 4 4 8 7 25 22 25 22 13 1
2
19 1
7
51 45
Total
Male 3,035 9 0 27 1 76 3 586 19 54 2 53 2 689 23
Female 3,595 20 1 45 1 52 1 697 19 62 2 60 2 802 22
% = Row PercentsBMC Health Services Research 2001, 1:8 http://www.biomedcentral.com/1472-6963/1/8
Table 2: Predictors of Influenza-Related Complications and Hospitalizations
Type of Complication
Hospitalization (N = 103) Any Complication (N = 1,545)
Episodes N % RR* N % RR*
Female 3,595 58 1.6 1.1 841 23.4 1.0
Male 3,035 45 1.5 - 704 23.2 -
Age
<5 1,221 11 0.9 0.6 347 28.4 1.3
5–14 1,632 8 0.5 0.3 344 21.1 1.0
15–24 589 2 0.3 0.2 123 20.9 1.0
25–34 729 7 1.0 0.6 149 20.4 1.0
35–44 975 15 1.5 - 210 21.5 -
45–54 806 18 2.2 1.5 165 20.5 1.0
55–64 508 27 5.3 3.5 139 27.5 1.3
65+ 170 15 8.8 5.7 68 40.0 1.9
Concurrent Conditions
Prior Immunization
Yes 160 11 6.9 4.8 48 30.0 1.3
No 6,470 92 1.4 – 1497 23.1 –
Recent Complication or Comorbidity
Yes 1,430 62 4.3 5.5 472 33.0 1.6
No 5,200 41 0.8 – 1073 20.6 –
Concurrent Dispensing of Amantadine or Rimantadine
Yes 267 3 1.1 0.7 66 24.7 1.1
No 6,363 100 1.6 - 1479 23.2 -
Prior Influenza Episode
Yes 389 3 0.8 0.5 92 23.7 1.0
No 6,241 100 1.6 - 1453 23.3 -
Quintile of 3-Month Preceding Health Care Cost
1:$0 1,436 10 0.7 273 19.0
2: >$0–$86 1,218 4 0.3 0.5 234 19.2 1.0
3:$87–$199 1,324 6 0.5 0.6 254 19.3 1.0
4: $200–452 1,326 16 1.2 1.7 346 26.1 1.4
5:$453+ 1,326 67 5.1 7.2 438 33.0 1.7
Evidence of Medication Use and Prevalent Comorbid Conditions
Chronic Corticosteroid Use
Yes 29 6 20.7 14.1 16 55.2 2.4
No 6,601 97 1.5 1529 23.2
Malignancy
Yes 72 15 20.8 15.5 39 54.2 2.4
No 6,558 88 1.3 – 1506 23.0 –
Chronic Heart Disease
Yes 128 22 17.2 13.7 60 46.9 2.1
No 6,502 81 1.3 – 1485 22.8 –
Chronic Lung Disease
Yes 1,283 37 2.9 2.3 364 28.4 1.3
No 5,347 66 1.2 – 1181 22.1 –
Diabetes
Yes 116 14 12.1 8.8 50 43.1 1.9
No 6,514 89 1.4 – 1495 23.0 –BMC Health Services Research 2001, 1:8 http://www.biomedcentral.com/1472-6963/1/8
Influenza/ILI-related complications and hospitalizations
Overall, 23% of intervals of care had an influenza/ILI-re-
lated complication. Respiratory complications were the
most common (13%). Approximately 2% of influenza/ILI
intervals of care resulted in a hospitalization for influen-
za/ILI-related complications. Four percent resulted in
an emergency room visit and 20% resulted in an office
visit (data not shown).
The median and mean length of hospital stay during the
observation period for influenza/ILI-related complica-
tions was 5 days. Including portions of hospitalizations
that extended outside of the 21-day observation period,
the median length of stay in hospital was still five days.
The mean was 8.4 days.
Table 2 shows the unadjusted associations for the poten-
tial predictors of influenza/ILI-related hospitalizations
and complications during the influenza/ILI intervals of
care. In general, the patterns seen for factors associated
with hospitalizations were similar to those seen for influ-
enza/ILI-related complications. Older age, prior immu-
nization, recent complications or co-morbid diagnoses
(30 days before the influenza/ILI diagnosis), co-morbid-
ities identified in the year prior to diagnosis, and high re-
cent health care costs (in the previous three months)
were all strongly associated with hospitalizations or
complications of influenza/ILI.
Table 3 presents the results from the logistic regression
analyses for predictors of any type of influenza/ILI-relat-
ed complication and hospitalization. Adults in the oldest
Table 3: Predictors of Influenza Complications and Hospitalziations
Presence During Interval of Care
Hospitalization (N = 103) Any Complication (N = 1,545)
OR* 95% Cl OR* 95% Cl
Sex (Female vs. Male) 1.02 0.67–1.56 1.00 0.89–1.12
Age
<5 0.75 0.33–1.70 1.55 1.26–1.91
5–14 0.45 0.19–1.10 1.08 0.89–1.32
15–24 0.28 0.06–1.26 1.02 0.79–1.31
25–34 0.83 0.33–2.07 0.99 0.78–1.26
35–44 1.00 n/a 1.00
45–54 1.22 0.59–2.52 0.85 0.67–1.08
55–64 1.75 0.87–3.52 1.04 0.80–1.35
65+ 1.93 0.82–4.56 1.54 1.06–2.24
Prior/Concurrent
Prior Immunization 2.17 1.06–4.43 1.01 0.70–1.45
Recent Comp/Comorbidity 3.17 1.96–5.13 1.47 1.27–1.70
Concurrent Amant/ Rimant 0.60 0.18–2.00 1.22 0.91–1.63
Prior Influenza Episode 0.32 0.09–1.07 0.85 0.66–1.09
Quintile of 3-Month Preceding Health Care Cost
1:$0 1.00 1.00
2: >$0–$86 0.38 0.22–1.22 0.92 0.75–1.12
3:$87–$199 0.44 0.15–1.24 0.86 0.70–1.04
4: $200–452 0.84 0.36–1.97 1.21 1.00–1.47
5:$453+ 1.71 0.77–3.84 1.56 1.28–1.91
Medication Use and Prevalent Comorbid Conditions
Chronic Corticosteroid Use 2.00 0.66–6.02 1.84 0.83–4.07
Malignancy 3.67 1.82–7.44 2.38 1.44–3.93
Chronic Heart Disease 3.16 1.66–6.00 1.76 1.19–2.61
Chronic Lung Disease 1.29 0.81–2.05 1.15 1.00–1.34
Diabetes 2.19 1.08–4.47 1.74 1.16–2.61
* Adjusted using logistic regression.BMC Health Services Research 2001, 1:8 http://www.biomedcentral.com/1472-6963/1/8
Table 4: Predictors of Costs Related to Influenza Complications and of Total Health Care Costs
Influenza-Related Costs Total Costs
Mean Median Mean Median
Gender
Female $303 $69 $409 $107
Male $294 $67 $380 $93
Age
0–4 $150 $62 $184 $83
5–14 $111 $61 $152 $69
15–24 $125 $69 $184 $100
25–34 $211 $68 $339 $103
35–44 $335 $77 $425 $118
45–54 $639 $80 $811 $141
55–64 $762 $93 $959 $182
65+ $944 $109 $1,408 $246
Prior/Concurrent Conditions
Prior Vaccination
Yes $1,264 $89 $1,453 $177
No $275 $68 $369 $100
Recently Preceding Complication or Comorbidity Diagnosis
Yes $776 $87 $944 $126
No $167 $66 $245 $93
Concurrent Dispensing of Amantadine or Rimantadine
Yes $177 $92 $320 $127
No $304 $67 $399 $100
Prior Influenza Episode
Yes $187 $76 $263 $106
No $306 $68 $404 $100
Quintile of 3-Month Preceding Health Care Cost
1:$0 $124 $62 $161 $71
2: >$0–$86 $104 $62 $140 $75
3:$87–$199 $132 $62 $178 $86
4: $200–452 $225 $75 $288 $114
5:$453+ $907 $100 $1,208 $211
Evidence of Medication Use and Prevalent Comorbid Conditions
Chronic Corticosteroid Use
Yes $1,505 $263 $1,763 $376
No $294 $68 $390 $100
Malignancy
Yes $5,180 $165 $5,904 $400
No $245 $68 $335 $100
Chronic Heart Disease
Yes $2,866 $162 $3,295 $334
No $248 $67 $338 $99
Chronic Lung Disease
Yes $510 $86 $637 $128
No $248 $66 $337 $94
Diabetes
Yes $1,949 $124 $2,290 $290
No $269 $68 $362 $100BMC Health Services Research 2001, 1:8 http://www.biomedcentral.com/1472-6963/1/8
age groups (55–64 and 65+) were nearly twice as likely to
be hospitalized (55–64 OR = 1.75; 95% CI = 0.87–3.52;
65+ OR = 1.93; 95% CI = 0.82–4.56), as were those in the
35–44 year old group. Patients with a recorded immuni-
zation were over 2.17 times as likely (95% CI 1.06–4.43)
to be hospitalized than patients without evidence of im-
munization. Intervals of care with recent influenza/ILI-
related complications or co-morbid diagnoses (within 30
days) were 3.2 times (95% CI 1.96–5.13) more likely to be
hospitalized compared to those without a recent concur-
rent complication. Episodes with the highest quintile of
medical care costs in the preceding three months had
about a 1.7 – fold increased likelihood of being hospital-
ized (95% CI 0.77–3.84). Prevalent co-morbid condi-
tions and medication use were generally associated with
an increased likelihood of hospitalization.
The logistic models for possible predictors of influenza/
ILI-related complications showed that children under
the age of five years (OR = 1.55; 95% CI = 1.26–1.91) and
adults over the age of 65 years were more likely (OR =
1.54; 95% CI = 1.06–2.24) to experience complications
when compared to the 35–44 age group. Intervals of care
for wpatients diagnosed with recent influenza/ILI-relat-
ed complications or co-morbid diagnosis (30 days prior)
were more likely (OR = 1.47; 95% CI 1.27–1.70) to result
in patients having influenza/ILI-related complications.
Higher quintiles for cost of medical services received in
the 3-month period preceding the influenza/ILI diagno-
sis were more strongly associated with complications of
influenza/ILI (4th quintile OR = 1.21; 95% CI = 1.00–
1.47; 5th quintile OR = 1.56; 95% CI = 1.28–1.91). Preva-
lent co-morbidities such as maligna (95% CI = 1.19–2.61)
and diabetes (OR = 1.74; 95% CI = 1.16–2.61) were signif-
icantly related to the occurrence of influenza/ILI-related
complications during intervals of care for influenza/ILI.
(Table 3)
Table 4 shows the total, mean and median costs incurred
on influenza/ILI diagnosis date and during the 21-day
follow-up period, stratified by possible predictor varia-
bles. Intervals of care for patients with prevalent co-mor-
bid conditions had a consistently higher median
influenza/ILI-related costs compared to those without
co-morbidities. Influenza/ILI-related costs accounted
for 76% of the total health care costs incurred during the
interval of care ($1,981,072 / $2,622,179).
Discussion
Elderly patients and patients with an underlying chronic
illness, a recent complication, or a higher health care cost
in the recent months were at the highest risk of hospital-
ization and complications after a diagnosis of influenza/
ILI. Influenza/ILI-related health care costs represented
the bulk of total health care costs during an influenza/ILI
interval of care. In addition to a confirmation of what we
would expect qualitatively for the healthcare burden of
influenza, our observation provides a useful quantitative
estimate for these effects in the general population.
The diagnosis of influenza/ILI was based on ICD-9 codes
and did not incorporate viral isolates or laboratory con-
firmation. "Influenza/ILI" in this study is likely to be
representative, on a population level, of influenza/ILI di-
agnoses and a smaller percentage of more severe influen-
za-like illness. The 21-day follow-up period incorporated
a clinical expectation that the vast majority of influenza/
ILI-related complications would occur within this peri-
od, and that complications that extended beyond 21 days
would usually be ascribable in part to pre-existing ill-
ness. More sophisticate approaches are imaginable, but
not among multiple causes, which in any case would
have been impossible to implement at the level of insur-
ance claims analysis.
This study found that patients with a record of an influ-
enza immunization were at a higher risk for hospitaliza-
tion than those who were not vaccinated. This is clearly
not a vaccine effect, but instead an effect attributable to
the kinds of patients in the United States who typically
received influenza vaccination in a doctor's office during
the period of the study. Vaccine is indicated for patients
at high risk of complications, and that risk applies just as
much to ILI, which presumably account for the great ma-
jority of events among vaccinated persons. Antiviral use
was not extensive, and the current study dates preceded
the introduction of zanamivir and oseltamivir. It appears
that zanamivir reduces the risk of complication in high-
risk patients. [12] We found some indication (although
not statistically significant) that use of amantadine and
rimantadine may have prevented hospitalizations (OR =
0.6) and substantially reduced costs.
Influenza/ILI adversely affects individuals with a variety
of chronic underlying conditions, supporting the Center
for Disease Control and Prevention Immunization rec-
ommendations for influenza immunization [15]. Unlike
other studies that have evaluated the cost-effectiveness
of influenza immunization [13–16], our data quantify a
major cost impact of ILI and influenza/ILI in a large pop-
ulation (over 6200 patients) with wide-variation in ages
and health status. These data may be useful in under-
standing the patient groups at high risk for influenza-re-
lated complications and assisting the cost-benefit
evaluation of a more universal influenza immunization
program for these patients.
Both chronic and acute manifestations of comorbid ill-
ness were strong, independent predictors of influenza/
ILI-related complications and hospitalizations. Addi-BMC Health Services Research 2001, 1:8 http://www.biomedcentral.com/1472-6963/1/8
tionally, health care costs in the three months before the
influenza/ILI episode serve as a surrogate for the overall
health status of a patient and could reflect the severity of
the underlying diseases. We were unable to evaluate the
effect of HIV infection, chronic renal disease, and immu-
nosuppressive therapy due to small number of patients
with these co-morbidities. These groups of patients are
at high risk for influenza/ILI-related complications and
health care costs. Therefore, our estimates are most like-
ly an under representation of the true burden of influen-
za/ILI.
The 21-day follow-up period incorporated a clinical ex-
pectation that the vast majority of influenza/ILI-related
complications would occur within this period, and that
complications that extended beyond 21 days would usu-
ally be ascribable in part to preexisting illness. We chose
the 21-day cutoff as a rough-and-ready, approximate
partition of mulitfactorial disease burden. More sophis-
ticate approaches are imaginable, but not among multi-
ple causes, which in any case would have been
impossible to implement at the level of insurance claims
analysis.
These data reflect patterns of care for influenza/ILI seen
within the NEI health care system. NEI beneficiaries who
sought medical care outside the NEI system would not be
captured in the claims data and are not included in this
analysis. This is probably a relatively small percentage of
patients and is unlikely to bias the results. More impor-
tantly, care for many respiratory conditions (especially
otitis media and acute bronchitis) was captured in this
study only as a complication of previously recognized in-
fluenza/ILI. If the original illness had been diagnosed
only as one of these conditions, it would never have en-
tered into the study. In addition, we lack data on patients
who did not seek medical care for influenza/ILI. Medica-
tions purchased outside the insurance plan (e.g. over-
the-counter) are not included in the database. Thus, in-
fluenza/ILI-related costs we report are likely to be an un-
der estimate of the true costs of medical care, and this is
only a fraction of the total societal cost, which would in-
clude at a minimum lost wages and productivity. NEI en-
rolls relatively few persons over the age of 65, due to the
availability of Medicare coverage for the elderly. The eld-
erly in NEI include those who are still working or who
formerly worked for the state or federal government and
therefore are not eligible for Medicare.
Approximately 78% of influenza isolates from the World
Health Organization Collaborating Laboratories were
type A and 22% were type B during the 1996 – 1997 in-
fluenza season. Type A influenza is thought to cause
more severe illness [17–19]. Therefore, the majority of
influenza/ILI diagnoses captured in the NEI system us-
ing ICD-9 codes would be expected to be type A and rep-
resent a higher proportion of true influenza illness than
ILI during the 1996–1997 influenza season.
Antiviral use was not extensive, and the current study
dates preceded the introduction of zanamivir and osel-
tamivir. We found some indication (although not statis-
tically significant) that antiviral use may have prevented
hospitalizations (OR = 0.6). The recent marketing of in-
fluenza antivirals may have an even greater impact on
the predictors of complications and health care related
costs of influenza.
Strengths of this study include the large cohort of ILI and
influenza cases (over 6200 patients) and the diversity of
the risk profiles for influenza/ILI-related complications
in this population. These data should be applicable to
other large health maintenance organizations and would
be useful for evaluating the burden of influenza/ILI in
these populations.
Conclusions
Recent acute events foretell complications of influenza,
as does underlying chronic illness. Most costs in the
three weeks following onset are for influenza/ILI-related
care.
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